Merck (MRK) Declares $0.45 Quarterly Dividend; 3.1% Yield
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Merck (MRK) Announces Positive CHMP Opinion for Pembrolizumab
May 22, 2015 7:25 AM EDTMSD, known as Merck (NYSE: MRK) in the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of pembrolizumab, the companys anti-PD-1 therapy, for the treatment of advanced (unresectable or metastatic) melanoma as both first-line therapy and in previously-treated patients. The CHMP positive opinion for pembrolizumab, which is based on data in more than 1,500 adult patients with advanced melanoma, will now be reviewed by the European Commission for central marketing authorization in the... More
Merck (MRK) Receives Positive EMA CHMP Opinion on KEYTRUDA as Advanced Melanoma Treatment
May 22, 2015 7:13 AM EDTMerck (NYSE: MRK) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, for the treatment of advanced (unresectable or metastatic) melanoma, as both first-line therapy and in previously treated patients. The CHMP positive opinion for KEYTRUDA, which is based on data in more than 1,500 adult patients with advanced melanoma, will now be reviewed by the European Commission for central marketing authorization in the European Union (EU).
Merck is committed to bringing... More
